Therapeutic thyroid hormone ligand patents 1998-2003

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 8, 2004, Pages 1169-1183

  Malm, Johan ^a  

^a Karo Bio   (Sweden)

Author keywords

Cardiac arrhythmia; Dyslipidaemia; Hyperthyroidism; Hypothyroidism; Metabolic disease; Obesity; Thyroid hormone agonist; Thyroid hormone antagonist

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMIDE; AMIODARONE; AXITIROME; AZAURACIL; BENZOFURAN DERIVATIVE; CARBIMAZOLE; DEETHYLAMIODARONE; EZETIMIBE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IODIDE; LEVOTHYROXINE; LIOTHYRONINE; MALONIC ACID DERIVATIVE; POTASSIUM PERCHLORATE; PROPYLTHIOURACIL; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE; THIAMAZOLE; THYROID HORMONE; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; THYROMIMETIC AGENT; THYROXINE; TIRATRICOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTERIOSCLEROSIS; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG USE; DRUG WITHDRAWAL; GENETIC REGULATION; HORMONE ACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTHYROIDISM; HYPOTHYROIDISM; METABOLIC DISORDER; NONHUMAN; OBESITY; PATENT; RECEPTOR AFFINITY; REVIEW; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; THYROID DISEASE; WEIGHT REDUCTION;

EID: 4344716086     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.8.1169     Document Type: Review

References (70)

1. RYONO DE, GROVER JG, MELLSTRÖM K: Chapter 12: Thyroid hormones and thyromimetics. In: Burger's Medicinal Chemistry and Drug Discovery (6th Ed., Vol. 3). Abraham JA (Ed.), John Wiley & Sons (2003).
2. LAZAR MA: Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr. Rev. (1993) 14:184-193.
3. 1-deficient mice is an intrinsic defect. Am. J. Physiol. (1998) 275:R640-R646.
4. FORREST D, VENNSTRÖM B: Functions of thyroid hormone receptors in mice. Thyroid (2000) 10:41-52.
5. TAKEDA K, SAKURAI A, DEGROOT LJ, REFETOFF S: Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-β gene. J. Clin. Endocrin. Metab. (1992) 74:49-55.
6. WAGNER RL, APRILETTI JW, McGRATH ME, WEST BL, BAXTER JD, FLETTERICK RJ: A structural role for hormone in the thyroid hormone receptor. Nature (1995) 378:690-697.
7. DARIMONT BD, WAGNER RL, APRILETTI JW et al.: Structure and specificity of nuclear receptor-coactivator interactions. Genes Devel. (1998) 12:3343-3356.
8. WAGNER RL, HUBER RB, SHIAU AK et al.: Hormone selectivity in thyroid hormone receptors. Mol. Endocrin. (2001) 15:398-410.
9. DOW RL, SCHNEIDER SR, PAIGHT ES et al.: Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands, potent, TRβ subtype-selective thyromimetics. Bioorg. Med. Chem. Lett. (2003) 13:379-382.
10. 1. J. Med. Chem. (2003) 45:1580-1588.
11. BECK-PECCOZ P, SARTORIO A, DE MEDICI C, GRUGNI G, MORABITO F, FAGLIA G: Dissociated thyromimetic effects of 3,5,3′ -triiodothyroacetic acid (TRIAC) at the pituitary and peripheral tissue levels. J. Endocrin. Invest. (1988) 11:113-118.
12. RENNER P, NOVARTIS PHARMA AG: Strategic planning, company communication (16 November 1999). (IDdb3 drug report: No. 347827).
13. HARWOOD HJ Jr, HAMANAKA ES: Modulators of dyslipidaemia. Emerg. Drugs (1998) 3:147-172.
14. KARO BIO AB: Press release (31 August 2001). Iddb3 drug report: No. 420745.
15. KARO BIO AB: Press release (27 March 2002). IDdb3 drug report: No. 480442.
16. GROVER G, MELLSTRÖM K, YE L et al.: Selective thyroid hormone receptor-activation: a strategy for reduction of weight, cholesterol, and Lp(a) with reduced cardiovascular liability. Proc. Natl. Acad. Sci. USA (2003) 100:10067-10072.
17. EBISAWA M, INOUE N, FUKASAWA H, SOTOME T, KAGECHIKA H: Thiazolidinediones with thyroid hormone receptor agonistic activity. Chem. Pharm. Bull. (1999) 47:1348-1350.
18. CHIELLINI G, APRILETTI JW, YOSIHHARA HA, BAXTER JD, RIBEIRO RCJ, SCANLAN TS: A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem. Biol. (1998) 5:299-306.
19. TROST SU, SWANSON E, GLOSS B et al.: The thyroid hormone receptor-β-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology (2000) 141:3057-3064.
20. BOWLER J, LILLEY TJ, PITTAM JD, WAKELINGG AE: Novel steroidal pure anti-estrogens. Steroids (1989) 54:71-91.
21. WAKELING AE, BOWLER J: Steroidal pure antioestrogens. J. Endocrin. (1987) 112:R7-R10.
22. YOSIHAHARA HAI, APRILETTI JW, BAXTER JD, SCANLAN TS: A designed antagonist of the thyroid hormone receptor. Bioorg. Med. Chem. Lett. (2001) 11:2821-2825.
23. BAXTER JD, GOEDE P, APRILLETTI JW et al: Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology (2002) 143:517-524.
24. CHIELLINI G, NGUYEN N-H, APRILETTI JW, BAXTER JD, SCANLAN TS: Synthesis and biological activity of novel thyroid hormone analogues: 50-aryl substituted GC-1 derivatives. Bioorg. Med. Chem. (2002) 10:333-346.
25. NGUYEN N-H, APRILETTI JW, LIMA ST, WEBB P, BAXTER JD, SCANLAN TS: Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J. Med. Chem. (2002) 45:3310-3320.
26. LIM W, NGUYEN N-H, YANG HY, SCANLAN TS, FURLOW JD: A thyroid hormone antagonist that inhibits thyroid hormone action in vivo. J. Biol. Chem. (2002) 277:35664-35670.
27. BORNGRAEBER S, BUDNY MJ, CHIELLINI G et al.: Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc. Natl. Acad. Sci. USA (2003) 100:15358-15363.
28. YOKOYAMA N, WALKER GN, MAIN AJ et al.: Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine. J. Med. Chem. (1995) 38: 695-707.
29. STANTON JL, CAHILL E, DOTSON R et al.: Synthesis and biological activity of phenoxyphenyl oxamic acid derivatives related to L-thyronine. Bioorg. Med. Chem. Lett. (2000) 10:1661-3.
30. HANGELAND JJ, DEJNEKA T, FRIENDS TJ et al.: Thyromimetics with improved selectivity for the thyroid hormone receptor β. The 226th ACS National Meeting, Division of Medicinal Chemistry. New York, USA (2003) MEDI 321.
31. RIBEIRO MO, GARCALHO SD, SCHULTZ JJ et al.: Thyroid hormonesymapthetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform-specific. J. Clin. Invest. (2001) 108:97-105.
32. DE LANGE P, LANNI A, BENEDUCE L et al.: Uncoupling protein-3 is a molecular determinant for the regulation of resting metabolic rate by thyroid hormone. Endocrinology (2001) 142:3414-3420.
33. MIRSKY IA, BROH-KNHA RH: Am. J. Physiol. (1936) 117:6.
34. CASLA A, ROVIRA A, WELLS JA, DOHM GL: Increased glucose transporter (GLUT4) protein expression in hyperthyroidism. Biochem. Biophys. Res. Commun. (1990) 171:182-188.
35. RAMOS S, GOYA L, ALVAREZ C et al.: Different role of insulin in GLUT-1 and -4 regulation in heart and skeletal muscle during perinatal hypothyroidism. Am. J. Physiol. Endocrinol. Metab. (2001) 281:E1073-E1081.
36. EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS (ADULT TREATMENT PANEL III): Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA (2001) 285:2486-2497.
37. UNDERWOOD AH, EMMETTH JC, ELLIS D et al.: A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature (1986) 324:425-9.
38. LEESON PD, EMMETTH JC, SHAH VP et al.: Selective thyromimetics. Cardiac-sparing thyroid hormone analogues containing 3′-arylmethyl substituents. J. Med. Chem. (1989) 32:320-336.
39. RAKOW AD, KLOR HU, KUTER E, DITSCHUNEIT HH, KITSCHENEIT H: Treatment of Type Il hyperlipoproteinemia with d-thyroxine. Atherosclerosis (1976) 24:369-380.
40. RIDGWAY ND, DOLPHIN PJ: Serum activity and hepatic secretion of lecithin cholesterol acyltransferase in experimental hypothyroidism and hypercholesterolemia. J. Lipid Res. (1985) 26:1300-1313.
41. SCARABOTTOLO L, TREZZI E, ROMA P, CATAPAN AL: Experimental hypothyroidism modulates the expression of the low density lipoprotein receptor by the liver. Atherosclerosis (1986) 59:329-333.
42. DE BRUIN TW, VAN BARLINGEN H, VAN LINDE-SIBENIUS TRIP M, VAN VUURST DE VRIES AR, AKVELD MJ, ERKELENS DW: Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthryoid, and hyperthyroid subjects. J. Clin. Endocrinol. Met. (1993) 76:121-126.
43. SINGH BN, VAUGHAN WILLIAMS EM: The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br. J. Pharmacol. (1970) 39:657-667.
44. LATHAM KR, SELETTI DF, GOLDSTEIN RE: The effects of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors. J. Am. Coll. Cardiol. (1987):472-450.
45. NORMAN MF, LAVIN TA: Competition of thyroid hormone action by amiodarone in rat pituitary tumor cells. J. Clin. Invest. (1989) 83:306-313.
46. BOSCH RF, Li G-R, GASPO R, NATTEL S: Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes. J. Pharmacol. Exp. Ther. (1999) 289:156-165.
47. SINGH BN. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am. J. Cardiol. (1996) 78:41-53.
48. KODAMA I, KAMIYA K, TOYAMA J: Cellular electropharmacology of amiodarone. Cardiovasc. Res. (1997) 35:13-29.
49. 1, whereas disopyramide, lignocaine, propafenone, metoprolol, dl-sotalol, and verapamil have no inhibitory effect. J. Cardiovasc. Pharmacol. (1995) 26:222-226.
50. 1-receptor protein. Mol. Cell. Endocrin. (1995 ) 112:15-19.
51. 1-receptor protein. Endocrinology (1994 ) 134:1665-1670
52. 1: in vitro and in vivo evidence. Endocrinology (2003) 144:552-558.
53. CARLSSON B, SINGH BN, TEMCIUC M et al.: Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB-130015) with an improved toxicity profile comared with amiodarone. J. Med. Chem. (2002) 45:623-630.
54. CHALMERS DK, MUNRO SLA, ISKANDER MN, CRAIK DJ: Models for the binding of amiodarone to the thyroid hormone receptor. J. Comput. Aided Mol. Des. (1992) 6:19-31.
55. SHAHRARA S, DRVOTA V, SYLVEN C: Organ specific expression of thyroid hormone receptor mRNA and protein in different human tissues. Biol. Pharm. Bull. (1999) 22:1027-1033.
56. BLANGE I, DRVOTA V, YEN PM, SYLVEN C: Species differences in cardiac thyroid hormone receptor isoforms protein abundance. Biol. Pharm. Bull. (1997) 20:1123-1126.
57. KAASIK A, SEPPET EK, OHISALO JJ: Enhanced negative inotropic effect of an adenosine A1-receptor agonist in rat left atria in hypothyroidism. J. Mol. Cell. Cardiol. (1994) 26:509-517.
58. EL-ANI D, JACOBSON KA, SHAINBERG A. Characterization of adenosine receptors in intact cultured heart cells. Biochem. Pharmacol. (1994) 48:727-735.
59. KLEIN I, OJAMAA K. Thyroid hormone and the cardiovascular system. N. Engl. J. Med. (2001) 344:501-509.
60. HORSLEY V: The thyroid gland: its relation to the pathology of myxoedema and cretinism, to the question of surgical treatment of goitre, an to the general nutrition of the body. Br. Med. J. (1885) 1:111-115.
61. 3. Endocrinology (1972) 91:934-947.
62. HUANG TS, CHOPRA IJ, BEREDO A, SOLOMON DH, CHUA TECO GN: Skin is an active site for the inner ring monodeiodination of thyroxine to 3,39,59-triiodothyronine. Endocrinology (1985) 117:2106-2113.
63. KAPLAN MM, PAN C, GORDON PR, LEE JK, GILCHREST BA: Human epidermal keratinocytes in culture convert thyroxine to 3,5,3′-triiodothyronine by Type II iodothyronine deiodination: A novel endocrine function of skin. J. Clin. Endocrinol. Metab. (1988) 66:815-822.
64. 3, and thyroid hormone (c-erb-A) nuclear receptors in human skin using reverse transcription and polymerase chain reaction. Acta Derm. Venereol. (1993) 73:102-107.
65. 1 is expressed in the human hair follicle. Br. J. Dermatol. (2000) 142:645-652.
66. TORMA H, KARLSSON T, MICHAELSSON G, ROLLMAN O, VAHLQUIST A: Decreased mRNA levels of retinoic acid receptor-α, retinoid X receptor-α and thyroid hormone receptor-α in lesional psoriatic skin. Acta Derm. Venereol. (2000) 80:4-9.
67. SAFER JD, FRASER LM, RAY S, HOLICK MF: Topical triiodothyronine stimulates epidermal proliferation, dermal thickening, and hair growth in mice and rats. Thyroid (2001) 11:717-724.
68. FAERGEMANN J, SARNHULT T, HEDNER E et al.: Dose-response effects of tri-iodothyroacetic acid (TRIAC) and other thyroid hormone analogues on glucocorticoid induced skin atrophy in the haired mouse. Acta Derm. Venereol. Scand. (2002) 82:179-183.
69. HOATH SB, LAKSHMANAN J, FISHER DA: Structure-activity relation of thyroid hormone analogues and tissue epidermal growth factor concentrations in neonatal and adult mice. Am. J. Dis. Child. (1984) 138:251-253.
70. BAXTER JD, DILLMANN WH, WEST BL et al.: Selective modulation of thyroid hormone receptor action. J. Steroid Biochem. Mol. Biol. (2001) 76:31.